



(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 405/12 (2006.01)

C07D 239/94 (2006.01) C07D 413/12 (2006.01)

C07D 401/12 (2006.01) A61K 31/517 (2006.01)

C07D 403/12 (2006.01)

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/080828

(22) International Filing Date:

02 December 2022 (02.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/287,857 09 December 2021 (09.12.2021) US

63/329,674 11 April 2022 (11.04.2022) US

(71) Applicant: **DECIPHERA PHARMACEUTICALS, LLC** [US/US]; 200 Smith Street, Waltham, Massachusetts 02451 (US).

(72) Inventors: **AHN, Yu Mi**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **CALDWELL, Timothy**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **FLYNN, Daniel L.**; 200 Smith Street, Waltham, Massachusetts 02451 (US). **LE BOURDONNEC, Bertrand**; 200 Smith Street, Waltham, Massachusetts 02451 (US).

(74) Agent: **CHOI, Boyeon** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC COMPOUNDS AS KIT KINASE INHIBITORS



Formula I

(57) Abstract: Described herein are compounds of Formula I that are inhibitors of wild type and oncogenic mutant c-KIT kinase and their use in the treatment of disorders such as cancers.

